Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Merck (NYSE:MRK), through Merck Animal Health, reported global survey results on canine allergic skin disease. Data from 1,710 dog owners and 1,413 veterinarians show high prevalence of itchy skin cases, treatment switching due to efficacy, safety and cost concerns, and a desire for rapid-onset, targeted, easier-to-administer antipruritic options, including for younger dogs and more affordable therapies.
Merck (NYSE:MRK) received FDA approval for KEYTRUDA and KEYTRUDA QLEX, each combined with WELIREG, as adjuvant treatment for adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, with or without metastasectomy.
Phase 3 LITESPARK-022 (1,841 patients) showed KEYTRUDA plus WELIREG cut the risk of disease recurrence, metastasis or death by 28% versus KEYTRUDA plus placebo (HR=0.72; p=0.0003), with 24‑month disease-free survival of 81% vs 74%. WELIREG carries a boxed warning for embryo‑fetal harm and can cause severe anemia and hypoxia.
Merck (NYSE:MRK), through Merck Animal Health, signed a definitive agreement to acquire biodevice innovator TARGAN for an undisclosed price.
The deal, expected to close in Q3 2026 pending regulatory approvals, would add TARGAN’s WingScan™ gender-identification system and high-speed ocular vaccine delivery technology for commercial poultry hatcheries worldwide.
Gilead and Merck (NYSE:MRK) reported positive topline Phase 3 results for once-weekly oral HIV regimen islatravir/lenacapavir (ISL/LEN). Both ISLEND-1 and ISLEND-2 met the Week 48 primary endpoint, showing statistical non-inferiority to daily BIKTARVY or standard of care, with generally comparable safety. The partners plan global regulatory filings.
Merck (NYSE: MRK) and Gilead announced discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus KEYTRUDA versus KEYTRUDA alone in previously untreated metastatic NSCLC patients with PD-L1 TPS ≥50%.
The eDMC recommended stopping after PFS failed to reach statistical significance and OS is unlikely to do so; safety was consistent with known profiles and no new safety signals emerged.
Apotex announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both eligible for 180-day shared exclusivity. These generics are AB rated to Merck’s JANUVIA and JANUMET and are indicated as adjuncts to diet and exercise for adults with type 2 diabetes.
The sitagliptin product comes in 25 mg, 50 mg, and 100 mg strengths, while the combination product is offered in 50 mg/500 mg and 50 mg/1,000 mg strengths. Both medicines are distributed through U.S. wholesalers and distributors.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced that chairman and CEO Robert M. Davis and Dr. Dean Y. Li, president of Merck Research Laboratories, will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for Tuesday, June 9, 2026, at 11:20 a.m. ET, with a live audio webcast accessible to investors, analysts, media, and the general public via an online weblink.
Merck (NYSE:MRK) and Moderna reported 5-year follow-up data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of intismeran autogene (mRNA-4157, V940) plus KEYTRUDA in high-risk stage III/IV melanoma after complete resection.
The combination reduced risk of recurrence or death by 49% and distant metastasis or death by 59% versus KEYTRUDA alone at a median 60.3-month follow-up, with a safety profile consistent with prior analyses.
Merck (NYSE: MRK) reported that the FDA granted Breakthrough Therapy designation to calderasib (MK-1084), an investigational oral KRAS G12C inhibitor, combined with KEYTRUDA for first-line treatment of advanced or metastatic KRAS G12C‑mutant NSCLC with PD‑L1 TPS ≥1%.
The designation is supported by positive Phase 1 KANDLELIT‑001 data and is accompanied by an extensive KANDLELIT Phase 3 program across NSCLC and CRC. Calderasib is being developed in collaboration with Taiho and Astex.
Merck (NYSE: MRK) announced that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, will join a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 10:30 a.m. ET.
A live audio webcast of the presentation will be available to investors, analysts, media, and the public via an online weblink.